Acrux libido drug readies for PII trials
07 May, 2003 by Melissa TrudingerAcrux subsidiary FemPharm is poised to commence a Phase II clinical trial testing its proprietary Metered Dose Transdermal System for the delivery of testosterone to women with low libido.
Day in the sun for EpiTan
07 May, 2003 by Jeremy TorrThe anti-sunburn drug Melanotan has turned a pallid lifesaver into a bronzed god, according to initial results from trials conducted at Sydney's Royal Prince Alfred Hospital.
Research institutes mine microarray gold
07 May, 2003 by Pete YoungSome publicly-funded Australian biotech research institutes are enjoying lucrative returns from selling the microarray fabrication skills of their scientists.
CSIRO applied to, but didn't, import wheat virus
06 May, 2003 by Pete YoungCSIRO was awarded a licence in 2001 to conduct a genetic research project using the wheat streak mosaic virus which is infesting a growing number of plant research facilities.
Novogen investigates fast track to local production
06 May, 2003 by Jeremy TorrFollowing highly successful Phase I trials, Sydney-based isoflavone biotech Novogen is considering fast-tracking FDA approval for its new anti-cancer drug Phenoxodiol.
Mouse ES cell advance welcomed
06 May, 2003 by Graeme O'NeillA US research team's demonstration that mouse embryonic stem (ES) cells can give rise to apparently normal egg cells in culture provides a "potentially superb" model for studying normal egg development and maturation in mammals, according to a Monash University stem cell expert.
New outbreak, but wheat virus fears could prove unfounded
06 May, 2003 by Melissa TrudingerA fourth outbreak of wheat streak mosaic virus, detected in research crops in Victoria today, has raised concerns that the virus may become a wider problem.
GTG expands testing services
06 May, 2003 by Melissa TrudingerGenetic Technologies (ASX: GTG) has expanded the range of testing services it can offer through the acquisition of animal testing service Genetic Science Services (GSS).
Four legs good
05 May, 2003 by Melissa TrudingerIt doesn't attract the limelight, but Australia's vet biotech sector is making strides, reports Melissa Trudinger
Plenty of scope for new gene discovery
05 May, 2003 by Melissa TrudingerWhat does a scientist do when he has a really interesting gene with blockbuster potential, but no clue about its function?
CSIRO reeling after wheat virus outbreak
02 May, 2003 by Melissa TrudingerIt's a nightmare scenario -- scientists forced to destroy months, even years of their labour to combat an outbreak of a virus never seen in Australia. And it has just happened at CSIRO Plant Industry, where thousands of plants have recently been destroyed to combat the wheat streak mosaic virus (WSMV), a cereal plant pathogen that has never before been identified in Australia.
GM pioneer points to thaw in public opposition
02 May, 2003 by Graeme O'NeillThere are signs that, even in the UK and Europe, consumer and political attitudes towards GM crops and foods are thawing, according to the scientist who has led the global campaign for GM agriculture, Prof Channapatna S Prakash.
Australian consumers don't mind GM: survey
02 May, 2003 by Graeme O'NeillA new survey suggests the great 'Frankenfood' scare could be over in Australia before it has even begun.
Back GM or see our agriculture markets wilt, conference told
02 May, 2003 by Melissa TrudingerAustralia runs the risk of being left behind if it does not adopt the production of GM crops, according to two recent reports presented at this week's Ag-Biotech Forum in Melbourne.
Ambri tightens its belt, looks for cash
01 May, 2003 by Pete YoungMedical diagnostics company Ambri is striving to tap fresh funding sources while engaging in further staff and cost cutbacks to stretch dwindling cash reserves.
